Dr. Agarwals Health Care IPO subscribed 1.55 times

Image
Last Updated : Jan 31 2025 | 5:50 PM IST

The offer received bids for 8.29 crore shares as against 5.35 crore shares on offer.

The initial public offer (IPO) of Dr. Agarwals Health Care received 8,29,80,520 bids for shares as against 5,35,26,172 shares on offer, according to stock exchange data at 17:30 IST on Thursday (30 January 2024). The issue was subscribed 1.55 times.

The issue opened for bidding on 29 January 2025 and it will close on 31 January 2025. The price band of the IPO is fixed between Rs 382 and Rs 402 per share. An investor can bid for a minimum of 35 equity shares and in multiples thereof.

The IPO comprises a fresh issue of equity shares worth up to Rs 300 crore and an offer for sale (OFS) of 6,78,42,284 equity shares aggregating up to Rs 2,727.26 crore by existing shareholders.

The objectives of the fresh issue include Rs 195 crore for the repayment/prepayment of certain borrowings, with the remaining amount allocated for general corporate purposes.

The promoters and promoter group hold an aggregate of 11,63,59,650 equity shares, aggregating to 37.73% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding is expected to be around 32.53%.

Ahead of the IPO, Dr. Agarwals Health Care on Tuesday, 28 January 2025, raised Rs 875.50 crore from anchor investors. The board allotted 2.17 crore shares at Rs 402 each to 43 anchor investors.

Dr. Agarwals Health Care offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.

Additionally, offers treatments such as glaucoma care, squint treatments, and oculoplasty surgeries, among others. Key surgical capabilities include intraocular lens procedures, corneal transplantation, pinhole pupilloplasty, single-pass four-throw pupilloplasty, and LASIK surgeries.

The firm reported a consolidated net profit of Rs 28.56 crore and sales of Rs 820.06 crore for the six months ended on 30 September 2024.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 31 2025 | 5:37 PM IST

Next Story